1Gelderblom H, Verweij J,Nooter K, a al. Cremophor EL:the drawbacks and advantages of vehicle selection for drug formulation [ J ]. Eur J Cancer ,2001,37:1590-1598.
2Nishyama N, Yokoyama M, Aoyaga T, et al. Preparation and characterization of serf-assembled polymer-metal complex micelle horn cis-dichlorodiammineplatinium (Ⅱ) and poly ( ethylene glycole )-poly (aspartic acid) block copolymer in an aqueous medium[J]. Langmuir,1999,15.
3Aliabadi HM, Mahmud A, Sharifabadi AD. Micelles of methoxy poly(ethylene oxide)-B-poly(-caprolactone) as vehicles for the solublization and controlled delivery of cyclosporin A[ J ]. J Control Release,2005,104(2) :301-311.
4Lavasanifar A,Samuel J, Kwon GS. The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly (ethylene oxide )-block-poly ( N-hexylstearate-L-aspartamide ) [J]. J Control Release ,2002,79(1-3) : 165-172.
5Yokoyama M,Satoh A,Sakurai Y, et al. Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size.[J]. J Control Release,1998,55(2-3) :219-229.
6Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer [J]. J Control Release ,2001,70(1-2) :63-70.
7Allen C, Han J, Yu YS, et al. Polycaprolactone-B-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone [J]. J Control Release ,2000,63(3) :275-286.
8Kataoka Kazunori, Matsumoto Tsuyoshi, Yokoyama M, et al. Doxorubicinloaded poly ( ethyleneglycol )-poly ( β-benzyl-L-aspartate ) copolymer micelles: Their pharmaceutical characteristics and biological significance[J], JControl Release,2000,64(1-3):143 - 153.
9Zhang X, Jackson JK, Burt HM. Development of amphiphilie diblock eopolymers as micellar carriers of taxol[J].Int J Pharm, 1996,132(1-2) : 195 - 206.
10Shuai X, Ai H, Nasongkla N, et al. Micellar carriers based on block copolymers of poly ( ξ-caprolactone ) and poly ( ethylene glycol ) for doxorubicin delivery[J]. J Control Release, 2004,98(3) :415 - 426.
